Agensys, Inc., an affiliate of Astellas Pharma Inc., specializes in therapeutic
antibody research and development in cancer. Agensys is developing a pipeline of
therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers.
The MAb product pipeline is being generated to Agensys' diverse portfolio of proprietary,
clinically relevant cancer targets that encompass 14 types of solid tumors. Agensys'
target portfolio and related products are protected by 119 issued/33 allowed patents
and over 300 applications. The Company has full capabilities to generate, develop
and manufacture antibody products.
Agensys is progressing a pipeline of both naked and antibody-drug conjugated (ADC)
therapeutic antibodies, directed at a variety of cancer indications, including those
of the prostate, kidney, pancreas, ovary, bladder, lung, colon, breast and skin.
ADC products are based on toxin platform technologies developed by Seattle Genetics.
Today, Agensys has a rich pipeline that includes four monoclonal antibody products
in clinical trials: (1) AGS-1C4D4, directed to Prostate Stem Cell Antigen (PSCA),
a novel target for prostate, pancreatic, and bladder cancers; (2) AGS-5ME, Agensys'
first ADC, directed to AGS-5, a novel target in multiple epithelial tumors, co-developed
with Seattle Genetics; (3) AGS-16M8F, an ADC developed for the treatment of metastatic
renal cancer; and (4) AGS-22M6E, an ADC developed for multiple solid tumors to include
breast, bladder, lung, and pancreatic cancers. Agensys' pre-clinical pipeline encompasses
over 10 different MAb programs.
Agensys in January 2011 broke ground on a new 160,000-square-foot, state-of-the-art
facility, which will help fulfill Astellas' mission of developing innovative pharmaceuticals
for cancer patients with still unmet medical needs. When completed in early 2013,
the campus will feature a pedestrian pathway, public café and a public sculpture
garden featuring art by local artists that will change annually.
"The research and development facility that is to be built on these grounds will
symbolize the promise of better days for cancer patients and their families around
the globe," said Agensys President and CEO Dr. Sef Kurstjens.
Agensys began operations in Santa Monica in 1997, founded by oncologists at UCLA.
In 2007, Astellas Pharma Inc. acquired Agensys with the plan to make it the center
of the company's antibody product discovery and development operations.